VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement

European Journal of Clinical Pharmacology

Volumn 66, Issue 6, 2010, Pages 591-598

  Puehringer, Helene ^a   Loreth, Ralph M ^b   Klose, Gudrun ^b   Schreyer, Brigitte ^b   Krugluger, Walter ^c,d   Schneider, Barbara ^e   Oberkanins, Christian ^a  

^a Vienna Lab Diagnostics GmbH   (Austria)

^b Westpfalz Klinikum GmbH   (Germany)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^d Donauspital ^*  (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Coumarins; CYP2C9; Dose variability; Phenprocoumon; VKORC1

Indexed keywords

CYTOCHROME P450 2C9; MENADIONE EPOXIDE; PHENPROCOUMON; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

3' UNTRANSLATED REGION; ADULT; AGED; ANTICOAGULATION; ARTICLE; DRUG DOSE REGIMEN; DRUG MECHANISM; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HOMOZYGOSITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; AGE; AUSTRIA; CAUCASIAN; GENETICS; GERMANY; HETEROZYGOTE; HOMOZYGOTE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; STATISTICAL MODEL;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; AUSTRIA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GERMANY; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHENPROCOUMON; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES;

EID: 77954915353     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0809-2     Document Type: Article

References (44)

1. Li T, Chang CY, Jin DY, Lin PJ, Khvovora A, Stafford D (2004) Identification of the gene for vitamin K epoxide reductase. Nature 427:541-544
2. Rost S, Fregin A, Ivaskevicius V et al (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537-541
3. Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EGD, Mumford AD (2005) Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost 93:23-26
4. Bodin L, Horellou MH, Flaujac C, Loriot MA, Samama MM (2005) A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J Thromb Haemost 3:1533-1535
5. Loebstein R, Dvoskin I, Halkin H et al (2007) A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109:2477-2480
6. D'Andrea G, D'Ambrosio RL, Perna D et al (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105:645-649
7. Rieder MJ, Reiner AP, Gage BF et al (2005) Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Doses. N Engl J Med 352:2285-2293
8. Wadelius M, Chen LY, Downes K et al (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5:262-270
9. Ufer M (2005) Comparative pharmacokinetics of vitamin K antagonists. Warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 12:1227-1246
10. Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G (2000) Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 84:775-778
11. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287:1690-1698
12. Voora D, Eby C, Linder MW et al (2005) Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 93:700-705
13. Hillman MA, Wilke RA, Yale SH et al (2005) A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 3:137-145
14. Hermida J, Zarza J, Alberca I, Montes R, Lopez ML, Molina E, Rocha E (2002) Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood 99:4237-4239
15. Tassies D, Freire C, Pijoan J, Maragall S, Monteagudo J, Ordinas A, Reverter JC (2002) Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 87:1185-1191
16. Bodin L, Verstuyft C, Tregouet DA et al (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106:135-140
17. Kirchheiner J, Ufer M, Walter EC et al (2004) Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and Sphenprocoumon in healthy volunteers. Pharmacogenetics 14:19-26 (Pubitemid 38183958)
18. Ufer M, Kammerer B, Kahlich R, Kirchheiner J, Yasar U, Brockmöller J, Rane A (2004) Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica 34:847-859
19. Carlquist JF, Horne BD, Muhlestein JB et al (2006) Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 22 (3):191-197
20. Schwarz U, Ritchie MD, Bradford Y et al (2008) Genomic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:999-1008
21. Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL (2008) An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarintreated patients. Thromb Haemost 100:229-239
22. Wadelius M, Chen LY, Lindh JD et al (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113:784-792
23. Schalekamp T, Brasse BP, Roijers JF et al (2006) VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 80:13-22
24. Spreafico M, Lodigiani C, van Leeuwen Y et al (2008) Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulation therapy. Pharmacogenomics 9:1237-1250
25. Schalekamp T, Oosterhof M, van Meegen E et al (2004) Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther 76:409-417
26. Schalekamp T, Brasse BP, Roijers JF et al (2007) VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: Interaction between both genotypes affects dose requirement. Clin Pharmacol Ther 81:185-193
27. Hummers-Pradier E, Hess S, Adham IM, Pieske B, Kochen MM (2003) Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur J Clin Pharmacol 59:213-219
28. Visser LE, van Vliet M, van Schaik RH et al (2004) The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14:27-33
29. Sconce EA, Khan TI, Wynne HA et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329-2333
30. Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr, Linder MW (2007) Estimation of warfarin maintenance dose based on VKORC1 (-1639G>A) and CYP2C9 genotypes. Clin Chem 53:1199-1205
31. Anderson JL, Horne BD, Stevens SM et al (2007) Randomized trial of genotyped-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116:2563-2570
32. Gage BF, Eby C, Johnson JA et al (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84:326-331
33. The International Warfarin Pharmacogenetics Consortium (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753-764
34. Oberkanins C, Moritz A, de Villiers JN, Kotze MJ, Kury F (2000) A reverse-hybridization assay for the rapid and simultaneous detection of nine HFE gene mutations. Genet Test 4:121-124
35. Montes R, Ruiz de Gaona E, Martinez-Gonzales MA, Alberca I, Hermida J (2006) The c.-1639G>A polymorphism if the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 133:183-187
36. Yuan HY, Chen JJ, Lee MTM et al (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Gen 14:1745-1751
37. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V et al (2006) The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Throm Haemost 95:782-787
38. Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G (2007) Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics 8:1545-1550
39. Cooper GM, Johnson JA, Langaee TY et al (2008) A genomewide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112:1022-1027
40. Takeuchi F, McGinnis R, Bourgeois S et al (2009) A genomewide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal Genetic Determinants of Warfarin Dose. PLoS Genet 5(3):e10000433
41. Caldwell MD, Awad T, Johnson JA et al (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111:4106-4112
42. Perez-Andreu V, Roldan V, Anton AI, Garcia-Barbera N, Corral J, Vicente V, Gonzalez-Conejero R (2009) Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 113:4977-4979
43. Good AC, Henz S (2007) A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res 120:921-925
44. Werner D, Werner U, Wuerfel A, Grosch A, Lestin HG, Eschenhagen T, Rau T (2009) Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing. Eur J Clin Pharmacol 65:783-788